8/106 sources · 5 publishersUpdated Oct 8, 18:08 UTC
CMA accepts Brink’s proposed remedy for NCR Atleos acquisition
The UK Competition and Markets Authority has accepted in principle Brink’s remedy to divest NoteMachine/TestLink UK, addressing competition concerns in its pending purchase of NCR Atleos. Brink’s said the divestiture will not affect the $200 million of annual run‑rate cost synergies it expects from the deal. The acquisition remains slated to close in early Q1 2027.
Why it matters
The regulator’s acceptance removes a major antitrust hurdle, allowing the transaction to proceed on schedule, which preserves the anticipated cost‑saving benefits for investors.
Key facts
- 1The CMA accepted in principle Brink’s proposed remedy for the NCR Atleos acquisition. globenewswire.com
- 2The remedy involves divesting NoteMachine/TestLink UK to avoid a Phase 2 referral. globenewswire.com
- 3Brink’s expects the divestiture will not impact $200 million in annual run‑rate cost synergies. globenewswire.com
- 4The acquisition is expected to close early in the first quarter of 2027. globenewswire.com
- 5Brink’s is engaging with prospective buyers for the NoteMachine/TestLink UK divestiture. globenewswire.com
- 6Mark Eubanks, President and CEO of Brink’s, commented on the CMA acceptance. globenewswire.com
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.